drugset
drugset / Trial / NCT04121286

A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China

NCT04121286 ↗

Phase 1 Completed 17 enrolled Allist Pharmaceuticals, Inc.
NaSequentialOpen-labelTreatment

Summary

This is a Phase 1, open-label dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) and assess the DLT of JAB-3312. It is anticipated that approximately 24 subjects will be enrolled in the dose-escalation phase of the study. JAB-3312 will be administered orally once daily (QD) in 21-day treatment cycles.

Timeline

Start
2020-07-14
Primary completion
2022-06-17
Completion
2022-06-17

Drugs

EvaluationDrugModalityDoseRoute
Subject JAB-3312 Unknown 1 mg Oral
Subject JAB-3312 Unknown 2 mg Oral
Subject JAB-3312 Unknown 4 mg Oral
Subject JAB-3312 Unknown 6 mg Oral
Subject JAB-3312 Unknown 8 mg Oral

Indications

breast cancer colorectal cancer esophageal squamous cell carcinoma head and neck squamous cell carcinoma non-small cell lung carcinoma pancreatic ductal adenocarcinoma